Distalmotion has closed a Series G funding round totalling $150m to expedite the expansion of its soft tissue robotic surgery system, DEXTER, in the US.
The funds will also be directed to support product and clinical development efforts that are currently underway.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The round was spearheaded by Revival Healthcare Capital, with participation from inside investors.
A central aspect of Distalmotion’s strategy is to target the Ambulatory Surgery Center (ASC) segment in the US.
DEXTER has already been in clinical practice across the US and Europe, with approximately 3,000 subjects receiving the treatment.
The system features wristed, one-time-use robotic instruments designed to increase precision and dexterity during operations.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIts compact and mobile design allows it to be used in any operating room without alterations, and can be transferred between rooms.
The system’s open architecture is said to allow for integration with both present and future operating room solutions such as advanced devices and visualisation systems used in supply chain workflows.
Distalmotion CEO Greg Roche said: “This funding marks another important milestone on our journey.
“The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations. As we enter our next phase of US market acceleration, ASCs represent a tremendous opportunity for DEXTER.”
In parallel to the funding round, the company has announced Chas McKhann as its board of directors’ executive chairman.
McKhann previously held CEO positions at publicly traded medical device firms, Apollo Endosurgery and Silk Road Medical.
McKhann said: “With the recent Food and Drug Administration (FDA) clearance in gynaecology and release of DEXTER product enhancements, the company is poised to accelerate adoption in the US and globally at this pivotal stage in its growth trajectory.”
